CLEO Diagnostics Ltd (AU:COV) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Cleo Diagnostics Ltd has announced that the Royal Women’s Hospital in Melbourne will join its ovarian cancer trial, expanding the trial’s Australian scope and enhancing patient sampling. This collaboration aims to optimize the company’s blood test for early detection of ovarian cancer, while also supporting its ongoing U.S. trials, which are on track for FDA submission in 2025. The initiative is part of Cleo’s broader strategy to accelerate market availability and engage international collaborators.
For further insights into AU:COV stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- M&A News: Paramount (PARA) Turned Down Apollo Global Management Seven Times
- Ford (NYSE:F) Calls for EV Incentives in the United Kingdom
- Intel’s (NASDAQ:INTC) $8B Payout Catches Workers’ Attention
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
